2022-RA-1371-ESGO Multiple-agent chemotherapy as first-line treatment for low risk gestational neoplasm: is it time or not? | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article info

Trophoblastic diseases

2022-RA-1371-ESGO Multiple-agent chemotherapy as first-line treatment for low risk gestational neoplasm: is it time or not?

Free

Authors

Fariba Yarandi Oncology, Tehran University Medical Science, Tehran, Iran, Islamic Republic of PubMed articles Google scholar articles
Elham Shirali Oncology, Tehran University Medical Science, Tehran, Iran, Islamic Republic of PubMed articles Google scholar articles
Zahra Haghi Shahid beheshti University, Tehran, Iran, Islamic Republic of PubMed articles Google scholar articles
Saeed Haghi Azad university, Tehran, Iran, Islamic Republic of PubMed articles Google scholar articles
Sara Ramhormozian Oncology, Tehran University Medical Science, Tehran, Iran, Islamic Republic of PubMed articles Google scholar articles

Citation

Yarandi F, Shirali E, Haghi Z, et al

2022-RA-1371-ESGO Multiple-agent chemotherapy as first-line treatment for low risk gestational neoplasm: is it time or not?

International Journal of Gynecologic Cancer 2022;32:A425.

Publication history

First published October 20, 2022.

Online issue publication

October 20, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.